OrthoPediatrics Corporation, a company dedicated to pediatric orthopedics, has announced its financial results for the first quarter of 2025. The company reported a total revenue of $52.4 million, marking a 17% increase from $44.7 million in the same period last year. This growth includes a 19% increase in domestic revenue and an 11% increase in international revenue. The company achieved an adjusted EBITDA of ($0.4) million, improving from ($1.1) million in the first quarter of 2024. OrthoPediatrics also reduced its first quarter 2025 free cash flow usage by 35% compared to the prior year and anticipates achieving its first full quarter of positive free cash flow by the fourth quarter of 2025. In terms of business developments, OrthoPediatrics expanded its scoliosis portfolio with the launch of the VerteGlide™ System, which is used to treat Early Onset Scoliosis. This launch marks the company's 80th system brought to market. Furthermore, the company has increased its full year 2025 revenue guidance to a range of $236.0 million to $242.0 million, representing growth of 15% to 18% over the prior year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.